Clinical Trials
임상시험 트래커
국내사는 전체 임상 이력, 글로벌 메이저는 진행 중 파이프라인을 추적합니다. ClinicalTrials.gov API v2에서 6시간 주기로 수집합니다.
기업
50 results
- 3상모집 중· Chronic Pruritus of Unknown Origin성인 원인불명만성소양증 환자에서 레미브루티닙의 유효성, 안전성 및 내약성 평가
A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
리드: 노바티스
- 3상모집 중· IgE-Mediated Food AllergyIgE 매개 식품 알레르기에서 레미브루티닙의 52주 연구
A 52-week Study of Remibrutinib in IgE-mediated Food Allergy
리드: 노바티스
- 3상모집 중· Chronic Pruritus of Unknown Origin원인불명 만성 소양증 환자를 대상으로 한 레미브루티니브의 유효성, 안전성 및 내약성 평가
A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
리드: 노바티스
- 3상모집 중· Berger Disease일차 IgA 신장병증 소아 환자에서 아트라센탄의 효능, 약동학, 안전성 및 내약성 평가 연구
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
리드: 노바티스
- 3상모집 중· Asthma12-18세 천식 소아의 QVM149와 살메테롤/플루티카손 비교 효능·안전성 연구
A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.
리드: 노바티스
- 3상모집 중· Sjögren´s Disease높은 증상 부담을 가진 쇼그렌병 환자에서 이아날루맙 대 위약의 효능 및 안전성을 평가하는 2군, 이중맹검, 3상 연구
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
리드: 노바티스
- 3상모집 중· Hidradenitis Suppurativa중등도~중증 화농성 한선염 환자에서 레미브루티닙의 장기 안전성과 효과 평가 확장 연구
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
리드: 노바티스
- 3상모집 중· Primary Myelofibrosis (PMF)골수섬유증에서 펠라브레시브(DAK539)와 루소리티닙의 3상 임상시험
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
리드: 노바티스
- 3상모집 중· Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)진행성 핵상마비 환자에서 NIO752의 유효성 평가
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
리드: 노바티스
- 3상모집 중· Cardiovascular Disease and Lipoprotein(a)펠라카센(TQJ230)의 장기 안전성 및 내약성 평가를 위한 공개표시 확장(OLE) 연구
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
리드: 노바티스
- 3상모집 중· Indication of the Parent Protocol레미브루티닙 공개표지 사후시험 접근 프로토콜
Remibrutinib Open Label Roll-over Post-trial Access Protocol
리드: 노바티스
- 3상모집 중· Huntington DiseaseA Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
리드: 노바티스
- 3상모집 중· Primary Immunoglobulin A Nephropathy (IgAN)Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
리드: 노바티스
- 3상모집 중· Secondary Progressive Multiple Sclerosis (SPMS)A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
리드: 노바티스
- 3상모집 중· Paroxysmal Nocturnal Hemoglobinuria (PNH)Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients
리드: 노바티스
- 3상모집 중· Acute Coronary SyndromeEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
리드: 노바티스
- 3상모집 중· Kidney DiseasesOpen-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
리드: 노바티스
- 3상모집 중· Prostate CancerStudy Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
리드: 노바티스
- 3상모집 중· Relapsing Multiple SclerosisEfficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
리드: 노바티스
- 3상모집 중· Somatostatin Receptor Positive (SSTR+)Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
리드: 노바티스
- 3상모집 중· Atherosclerotic Cardiovascular Disease (ASCVD)Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
리드: 노바티스
- 3상모집 중· Familial Hypercholesterolemia - HomozygousStudy to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
리드: 노바티스
- 3상모집 중· Generalized Myasthenia GravisA Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
리드: 노바티스
- 3상모집 중· Familial Hypercholesterolemia - HeterozygousStudy to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
리드: 노바티스
- 3상모집 중· Prostate Cancer MetastaticStandard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
협력: 노바티스
- 3상모집 중· Hematologic MalignancyAn Extension Study for Patients Previously Enrolled in Studies With Pelabresib
리드: 노바티스
- 3상모집 중· Prostate Cancer MetastaticA Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer
협력: 노바티스
- 3상모집 중· Systemic Lupus ErythematosusPhase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
리드: 노바티스
- 3상모집 중· Atypical Hemolytic Uremic SyndromeEvaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS
리드: 노바티스
- 3상모집 중· Oligometastatic Prostate Cancer (OMPC)An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
리드: 노바티스
- 3상모집 중· Atypical Hemolytic Uremic SyndromeEfficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
리드: 노바티스
- 3상모집 중· Sickle Cell Anemia in ChildrenPromoting Utilization and Safety of Hydroxyurea Using Precision in Africa
협력: 노바티스
- 3상모집 중· Heterozygous or Homozygous Familial HypercholesterolemiaLong-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies
리드: 노바티스
- 3상모집 중· Ovarian Neoplasm EpithelialMAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
협력: 노바티스, 로슈
- 3상모집 중· B-cell Acute Lymphoblastic LeukemiaStudy of Out of Specification for Tisagenlecleucel
리드: 노바티스
- 3상모집 중· Polycythemia VeraMITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
협력: 노바티스
- 3상모집 중· C3 GlomerulopathyLong-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
리드: 노바티스
- 3상모집 중· Non-metastatic Soft-tissue SarcomaBenefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas
협력: 노바티스
- 3상모집 중· Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access ProgramCAR-T Long Term Follow Up (LTFU) Study
리드: 노바티스
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.